Federal Register / Vol. 70, No. 182 / Wednesday, September 21, 2005 / Notices 55399 

E. Process by which the nominating 

organization will measure the use of 

these products and impact of such use. 

6. Topic Selection 

Factors that will be considered in the 

selection of topics for AHRQ evidence 

report and technology assessment topics 

include: 

A. Burden of disease including 

severity, incidence and/or prevalence or 

relevance of the organization/financial 

topic to the general population and/or 

AHRQ’s priority; 

B. Controversy or uncertainty about 

the topic and availability of scientific 

data to support the systematic review 

and analysis of the topic; 

C. Total costs associated with a 

condition, procedure, treatment, 

technology, or organization/financial 

topic taking into account the number of 

people needing such care, the unit cost 

of care, and related or indirect costs; 

D. Potential for reducing clinically 

significant variations in the prevention, 

diagnosis, treatment, or management of 

a disease or condition; or in changing 

the use of a procedure or technology; 

informing and improving patient and/or 

provider decision making; improving 

health outcomes; and/or reducing costs; 

E. Relevance to the needs of the 

Medicare, Medicaid and other Federal 

healthcare programs; and 

F. Nominating organization’s plan to 

disseminate derivative products, 

measure use and impact of these 

products on outcomes, or otherwise 

incorporate the report into its 

managerial or policy decision making. 

7. Submission of Nominations 

Topics nominations should be 

submitted to Kenneth Fink, MD, MGA, 

MPH, Director Evidence-based Practice 

Centers (EPC) Program, Center for 

Outcomes and Evidence, AHRQ, 540 

Gaither Road, Rockville, MD 20850. 

Electronic submissions to epc@ahrq.gov 

are preferred. 

Dated: September 12, 2005. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 05–18870 Filed 9–20–05; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30 Day–05–04OP] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 371–5983. Send written 

comments to CDC, Desk Officer, Human 

Resources and Housing Branch by fax to 

(202) 395–6974. Written comments 

should be received within 30 days of 

this notice. 

Proposed Project 

Delayed Symptoms Associated with 

the Convalescent Period of a Dengue 

Infection—New—National Center for 

Infectious Diseases (NCID), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Dengue is a vector-borne febrile 

disease of the tropics transmitted most 

often by the mosquito Aedes aegypti. 

Symptoms of the acute disease include 

fever, headache, rash, retro-orbital pain, 

myalgias, arthralgias, vomiting, 

abdominal pain and hemorrhagic 

manifestations. 

A number of symptoms are mentioned 

in the medical literature as associated 

with the convalescent period after 

dengue infection, including depression, 

dementia, loss of sensation, paralysis of 

lower and upper extremities and larynx, 

epilepsy, tremors, manic psychosis, 

amnesia, loss of visual acuity, hair loss, 

and peeling of skin. The evidence for 

these findings has derived mainly from 

case series and case reports, but no 

analytic study has been conducted to 

define the timing, frequency, and 

severity of these symptoms, and 

quantity the magnitude of the 

association between dengue infection 

and each of these disorders. 

The objective of this study is to 

compare mental health disorders and 

other delayed complications associated 

with dengue infection and 

convalescence among study groups. The 

study will be conducted in Puerto Rico, 

where dengue is endemic, in 

collaboration with Dengue Branch of the 

Centers for Disease Control and 

Prevention. Laboratory positive 

confirmed cases of dengue, laboratory 

negative suspected dengue cases, and 

neighborhood controls will be 

prospectively enrolled in the study. 

Telephone interviews will be conducted 

and information will be collected 

prospectively regarding symptoms 

experienced during the first five months 

after the onset of symptoms of a dengue 

infections. There are no costs to the 

respondents other than their time. The 

estimated annualized burden is 426 

hours. 

ESTIMATED TOTAL ANNUALIZED BURDEN HOURS

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

per response 

(in hrs.) 

Screeners ............................................................................................................................... 810 2 1/60 

Laboratory positive confirmed dengue .................................................................................. 200 2 20/60 

Dengue negative control ........................................................................................................ 200 2 20/60 

Neighborhood control ............................................................................................................ 200 2 20/60 

55400 Federal Register / Vol. 70, No. 182 / Wednesday, September 21, 2005 / Notices 

Joan Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 05–18786 Filed 9–20–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

(30 Day–05–04KJ) 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 371–5983 or send an 

email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Human 

Resources and Housing Branch, New 

Executive Office Building, via fax to 

(202) 395–6974. Written comments 

should be received within 30 days of 

this notice. 

Proposed Project 

Evaluation of the Poison HELP 

Campaign—to Enhance Public 

Awareness of the National Poison TollFree Number, Poison Center Access and 

Poison Prevention—New—The National 

Center for Injury Prevention and Control 

(NCIPC). 

Background and Brief Description 

Every day more than 6,000 calls about 

poison emergencies are placed to poison 

control centers (PCCs) throughout the 

United States. Although PCCs clearly 

save lives and reduce healthcare costs, 

the system that delivers care and 

prevents poisoning is comprised of 

more than 131 telephone numbers and 

thousands of disjointed local prevention 

efforts. 

As a result a national media campaign 

was launched to establish a national 

toll-free helpline entitled Poison Help 

(1–800–222–1222) that the general 

public, health professionals, and others 

can use to access poison emergency 

services and prevention information 24 

hours a day, seven days a week. The 

Poison Help campaign is the only 

national and regional media effort to 

promote awareness and use of the 

national toll-free number. The 

prospective audience for the Poison 

Help campaign is very broad—any 

person at any time is a potential user. 

To evaluate the campaign’s current 

performance a General Population 

Survey will be conducted with 2,500 

households in the United States. The 

General Population Survey supplies 

unique and essential information that 

provides CDC and HRSA with data on 

variations in awareness and use of the 

national toll-free number. These data 

will also suggest which campaign 

messages about poison prevention or 

available PCC services have resonated 

most strongly with various audiences. 

Results will be used to make 

comparisons with future evaluation 

activities and to make improvements to 

future campaign efforts. There is no cost 

to respondents other than their time. 

The total annualized estimated burden 

hours are 382. 

ESTIMATED ANNUALIZED BURDEN TABLE

Respondents Number of 

respondents 

Number of 

responses/respondent 

Average burden/response 

(in hours) 

Screened Households ........................................................................................................... 2,940 1 1/60 

Survey Respondents ............................................................................................................. 2,500 1 8/60 

Dated: September 15, 2005. 

Betsey S. Dunaway, 

Acting Reports Clearance Officer, Office of 

the Chief Science Centers for Disease Control 

and Prevention. 

[FR Doc. 05–18790 Filed 9–20–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Government-Owned Inventions: 

Availability for Licensing and 

Cooperative Research and 

Development Agreements (CRADAs) 

AGENCY: Centers for Disease Control and 

Prevention, Technology Transfer Office, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The invention named in this 

notice is owned by agencies of the 

United States Government and is 

available for licensing in the United 

States (U.S.) in accordance with 35 

U.S.C. 207, and is available for 

cooperative research and development 

agreements (CRADAs) in accordance 

with 15 U.S.C. 3710a, to achieve 

expeditious commercialization of 

results of federally funded research and 

development. A U.S. non-provisional 

patent application and a PCT 

application have been filed. National 

stage foreign patent applications 

claiming priority to the PCT application 

are expected to be filed within the 

appropriate deadlines to extend market 

coverage for U.S. companies and may 

also be available for licensing. 

ADDRESSES: Licensing and CRADA 

information, and information related to 

the technology listed below, may be 

obtained by writing to Suzanne Seavello 

Shope, J.D., Technology Licensing and 

Marketing Scientist, Technology 

Transfer Office, Centers for Disease 

Control and Prevention (CDC), Mailstop 

K–79, 4770 Buford Highway, Atlanta, 

GA 30341, telephone (770) 488–8613; 

facsimile (770) 488–8615; or e-mail 

sshope@cdc.gov. A signed Confidential 

Disclosure Agreement (available under 

Forms at http://www.cdc.gov/tto) will be 

required to receive copies of 

unpublished patent applications and 

other information. 

Diagnostics 

Development of Real-Time PCR Assay 

for Detection of Pneumococcal DNA and 

Diagnosis of Pneumococcal Disease 

The ability to diagnose pneumococcal 

pneumonia is limited by the lack of a 

sensitive, specific, and accurate 

laboratory assay. Using the PsaA 

(pneumococcal protein A) protein gene, 

CDC researchers have designed unique 

primers and probes and developed a 

real-time PCR assay for detection of 

pneumococcal DNA in serum and other 

sterile site body fluids for the diagnosis 

of pneumococcal disease. The PCR 

assay provides a tool for accurate 

diagnosis by clinicians, and for 

determination of the effectiveness 

(efficacy) of newly licensed 

pneumococcal polysaccharide-conjugate